格隆汇8月13日丨海创药业(688302.SH)公布2025年半年度报告，报告期实现营业收入1316.71万元，同比 增长0.84%；归属于上市公司股东的净利润-6185.32万元元；基本每股收益-0.62元。报告期内，公司实 现营业收入大幅增长，主要系公司首个1类新药氘恩扎鲁胺软胶囊（项目号：HC-1119）于2025年5月29 日获批上市，实现药品销售收入1,306.88万元，而上年同期营业收入仅为少量材料销售收入。 ...

Core Insights - Adidas reported a 7% year-on-year revenue growth for FY2025H1, reaching €12.105 billion, with a net profit increase of 121% to €798 million [4] - The brand's revenue growth was 14% on a currency-neutral basis, with all regional markets achieving double-digit growth [4] - The company maintains its full-year guidance, expecting high single-digit revenue growth on a currency-neutral basis for FY2025, with double-digit growth for the Adidas brand [4] Market Trends - The domestic market indices showed positive performance, with the Shanghai Composite Index closing at 3,617.60, up 0.96% [3] - The textile and apparel sector experienced a decline of 2.14% this week, underperforming the broader market [5] - Retail sales of sports and entertainment products grew significantly, with a 22.2% year-on-year increase in the first half of 2025 [5] Industry Dynamics - The Chinese gold consumption in the first half of 2025 was 505.205 tons, a decrease of 3.54% year-on-year, with jewelry consumption dropping by 26% [5] - The pharmaceutical industry is seeing advancements in innovative drugs, particularly in obesity treatments with GLP-1 and Amylin therapies showing promising results in clinical trials [8][11] - In the biopharmaceutical sector, ADC drugs for lung cancer are demonstrating significant efficacy, with several products showing improved outcomes in clinical trials [10][12]

Core Viewpoint - Haichuang Pharmaceutical has shown significant financing activity, indicating potential investor interest and market confidence in the company [1] Financing Activity - Haichuang Pharmaceutical recorded a net financing inflow of 77.53 million RMB last week, ranking 115th in the market [1] - The total financing amount for the week was 210 million RMB, with repayments amounting to 132 million RMB [1] Capital Flow - Over the past 5 days, the main capital inflow into Haichuang Pharmaceutical was 47.83 million RMB, with a price increase of 3.91% [1] - In the last 10 days, the main capital inflow was 58.37 million RMB, with a price increase of 2.27% [1] Company Profile - Haichuang Pharmaceutical Co., Ltd. was established in 2013 and is located in Chengdu, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 990.16 million RMB and a paid-in capital of 690.11 million RMB [1] - The legal representative of the company is Yuanwei Chen [1] Investment and Intellectual Property - Haichuang Pharmaceutical has invested in 2 external companies and participated in 15 bidding projects [1] - The company holds 23 trademark registrations and 71 patents, along with 89 administrative licenses [1]

特此公告。 海创药业股份有限公司 董事会 证券代码：688302 证券简称：海创药业 公告编号：2025-032 海创药业股份有限公司 关于持股 5%以上股东权益变动触及 5%刻度的提示性公告 信息披露义务人成都盈创动力创业投资有限公司保证向本公司提供的信息真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 权益变动方向 比例增加□ 比例减少? 权益变动前合计比例 10.67% 权益变动后合计比例 5.00% 本次变动是否违反已作出的承 是□ 否? 诺、意向、计划 是否触发强制要约收购义务 是□ 否? 一、 信息披露义务人及其一致行动人的基本信息 □控股股东/实际控制人及其一致行动人 ?其他 5%以上大股东及其一致行动人 投资者及其一致行动人的身份 □合并口径第一大股东及其一致行动人 □其他/ 信息披露义务人名称 投资者身份 统一社会信用代码 □控股股东/实控人 成都盈创动力创业投 □控股股东/实控人的一致行动 ?91510100551053934N□ 资有限公司 人 不适用 ?其他直接持股股东 上述信息披露义务人无一致 ...

海创药业股份有限公司 上市公司名称：海创药业股份有限公司 股票上市地点：上海证券交易所 股票简称：海创药业 股票代码：688302 信息披露义务人：成都盈创动力创业投资有限公司 注册地址：中国（四川）自由贸易试验区成都高新区天府大道北段 1480 号高新孵化园 12 号楼 A 座 103 号 通讯地址：中国（四川）自由贸易试验区成都高新区天府大道北段 1480 号高新孵化园 12 号楼 A 座 103 号 权益变动性质： 股份减少（持股比例下降至 5%） 签署日期：2025 年 7 月 31 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》 《中 华人民共和国证券法》 《上市公司收购管理办法》 《公开发行证券的公 司信息披露内容与格式准则第 15 号——权益变动报告书》及其他相 关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行 亦不违反信息披露义务人公司章程或内部规则中的任何条款，或与之 相冲突。 三、依据《中华人民共和国证券法》 《上市公司收购管理办法》和《公 开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-032 | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 10.67% | | | | 权益变动后合计比例 | 5.00% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否 | | | 是否触发强制要约收购义务 | 是□ | 否 | | 海创药业股份有限公司 关于持股 5%以上股东权益变动触及 5%刻度的提示性公告 信息披露义务人成都盈创动力创业投资有限公司保证向本公司提供的信息真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | | | | □合并口径第一大股东及其一致行动人 | | | □其他/ | 2.信息披露义务人信息 | 信 ...

海创药业股份有限公司 简式权益变动报告书 上市公司名称：海创药业股份有限公司 股票上市地点：上海证券交易所 股票简称：海创药业 股票代码：688302 信息披露义务人：成都盈创动力创业投资有限公司 注册地址：中国（四川）自由贸易试验区成都高新区天府大道北段 1480 号高新孵化园 12 号楼 A 座 103 号 通讯地址：中国（四川）自由贸易试验区成都高新区天府大道北段 1480 号高新孵化园 12 号楼 A 座 103 号 权益变动性质： 股份减少（持股比例下降至 5%） 签署日期：2025 年 7 月 31 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司收购管理办法》《公开发行证券的公 司信息披露内容与格式准则第 15 号——权益变动报告书》及其他相 关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行 亦不违反信息披露义务人公司章程或内部规则中的任何条款，或与之 相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》和《公 开发行证券的公司信息披露内容与格式准则第 15 号— ...

Group 1 - The financing balance of the Sci-Tech Innovation Board increased by 115 million yuan compared to the previous day, marking an increase for eight consecutive trading days [1] - As of July 23, the total margin financing balance on the Sci-Tech Innovation Board reached 165.993 billion yuan, with a financing balance of 165.389 billion yuan [1] - There are 435 stocks on the Sci-Tech Innovation Board with a financing balance exceeding 100 million yuan, and 17 stocks have a financing balance over 1 billion yuan [1] Group 2 - The stock with the highest net financing purchase is Shangwei New Materials, with a latest financing balance of 26.818 million yuan, increasing by 94.9546 million yuan, and the stock rose by 19.73% on that day [2] - Other stocks with significant net purchases include Electric Wind Power and Haichuang Pharmaceutical, with net purchases of 66.8525 million yuan and 54.0988 million yuan, respectively [2] - The average increase for stocks with net purchases exceeding 10 million yuan was 0.84%, with Electric Wind Power and Shangwei New Materials leading the gains [2] Group 3 - The industry sectors favored by financing customers include pharmaceuticals, electronics, and machinery, with 13, 12, and 11 stocks respectively [2] - The average ratio of financing balance to circulating market value for stocks with significant net purchases is 4.49%, with Xinyu Ren having the highest ratio at 9.53% [2] - Other stocks with high financing balance ratios include Huahai Chengke, Yangguang Nuohuo, and Yinuosi, with ratios of 8.49%, 8.31%, and 8.00% respectively [2]

Summary of Key Points Core Viewpoint - On July 18, a total of 16 stocks on the Sci-Tech Innovation Board (STAR Market) experienced block trading, with a cumulative transaction amount of 171 million yuan, indicating active trading activity in this sector [1]. Group 1: Trading Activity - A total of 31 block trades were recorded, with a cumulative trading volume of 4.8367 million shares [1]. - The stock with the highest transaction amount was Haitan Ruisheng, which had 9 block trades totaling 38.30 million shares and a transaction amount of 38.30 million yuan [1]. - Other notable stocks in terms of transaction amounts included Guangyun Technology and Fuchuang Precision, with transaction amounts of 24.9162 million yuan and 20.9360 million yuan, respectively [1]. Group 2: Price and Discount Analysis - The stocks that experienced the highest discount rates relative to their closing prices included Qingyun Technology, Weixin Bio, and Guangyun Technology, with discount rates of 19.48%, 17.25%, and 14.95%, respectively [1]. - The average increase for the stocks involved in block trading was 2.55%, with the top gainers being Dema Technology, Qingyun Technology, and Huasheng Lithium, which saw increases of 14.74%, 7.90%, and 7.22% respectively [1]. Group 3: Institutional Participation - Among the block trades, 12 transactions involved institutional buyers or sellers, with the highest buying amounts for Haitan Ruisheng, Guangyun Technology, and Qingyun Technology, at 27.70 million yuan, 11.2276 million yuan, and 7.579 million yuan, respectively [2]. - In terms of net capital flow, six stocks saw net inflows, with Dema Technology, Huasheng Lithium, and Qingyun Technology leading with net inflows of 51.1035 million yuan, 33.284 million yuan, and 32.1246 million yuan, respectively [2].

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]